• 1.

    Saroufim M, Charafeddine K, Issa G, Khalifeh H, Habib RH, Berry A, Ghosn N, Rady A, Khalifeh I , 2014. Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg Infect Dis 20: 17121715.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Hayani K, Dandashli A, Weisshaar E , 2015. Cutaneous leishmaniasis in Syria: clinical features, current status and the effects of war. Acta Derm Venereol 95: 6266.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    World Health Organization , 2014. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region. WHO Reg Publ East Mediterr Ser 35: 149.

    • Search Google Scholar
    • Export Citation
  • 4.

    Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, Kolaczinski J, David JR , 2005. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40: 11481155.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Solomon M, Schwartz E, Pavlotsky F, Sakka N, Barzilai A, Greenberger S , 2014. Leishmania tropica in children: a retrospective study. J Am Acad Dermatol 71: 271277.

  • 6.

    Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E , 2008. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19: 394396.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Asilian A, Sadeghinia A, Faghihi G, Momeni A , 2004. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 43: 281283.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Slape DR, Kim EN, Weller P, Gupta M , 2019. Leishmania tropica successfully treated with photodynamic therapy. Australas J Dermatol 60: e64e65.

  • 9.

    Morizot G et al.2013. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis 57: 370380.

  • 10.

    Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, Sakhayee I, Bogdan C, Stahl KW , 2014. A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan. BMC Infect Dis 14: 619.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Kirchberger MC, Schliep S, Bogdan C , 2019. Rhinophyma-like cutaneous leishmaniasis due to Leishmania aethiopica treated successfully with liposomal amphotericin B. Am J Trop Med Hyg 100: 231232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, Amin FM, Bogdan C, Stahl KW , 2014. Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul. PLoS Negl Trop Dis 8: e2694.

    • Search Google Scholar
    • Export Citation
  • 13.

    Hinz J, Hautzinger H, Stahl KW , 1986. Rationale for and results from a randomised, double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Lancet 1: 825828.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Tissot M, Roch-Arveiller M, Mathieu J, Giroud JP, Stahl KW , 1990. Anti-inflammatory properties of a novel wound healing and immunomodulating agent, tetrachlorodecaoxygen complex (TCDO). Agents Actions 31: 368374.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Naviaux RK , 2012. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther 342: 608618.

Past two years Past Year Past 30 Days
Abstract Views 15637 15637 38
Full Text Views 33 33 2
PDF Downloads 38 38 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Case Report: Local Treatment of a Leishmania tropica Infection in a Syrian Child with a Novel Filmogenic Preparation of Pharmaceutical Sodium Chlorite (LeiProtect®)

View More View Less
  • 1 Department of Dermatology, Paracelsus Medizinische Privatuniversität, Klinikum Nürnberg, Prof.-Ernst-Nathan-Straße 1, Germany;
  • | 2 Institute for Inorganic and Analytical Chemistry and Freiburg Material Research Center (FMF), Albert-Ludwigs-University Freiburg, Albertstraße 21, Freiburg, Germany;
  • | 3 Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Albert-Ludwigs-Universität, Hermann-Herder-Straße 9, Freiburg, Germany;
  • | 4 Pharmacy Department, Universitätsklinikum Erlangen, Palmsanlage 3, Erlangen, Germany;
  • | 5 Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstraße 3/5, Erlangen, Germany;
  • | 6 Medical Immunology Campus Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossplatz 1, Erlangen, Germany;
  • | 7 Waisenmedizin e. V. Promoting Access to Care with Essential Medicine (PACEM), Non-Profit Non-Governmental Organization, Günterstalstraße 60, Freiburg, Germany
Restricted access

ABSTRACT.

Cutaneous leishmaniasis (CL) frequently entails chronic skin lesions that heal only slowly. Until now, the available therapeutic options are very limited. Here, we present a case of a 5½-year-old Syrian refugee with two progressive lower-leg skin ulcers caused by Leishmania tropica. The patient received topical treatment with LeiProtect®, a newly developed, hydroxypropylcellulose-based, filmogenic gel containing nontoxic concentrations of pharmaceutical sodium chlorite. The skin lesions completely healed within 8 weeks and did not relapse during 1 year of follow-up, underlining the efficacy of this novel local therapy of CL.

Author Notes

Address correspondence to Christian Bogdan, Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstraße 3/5, D-91054 Erlangen, Germany, E-mail: christian.bogdan@uk-erlangen.de or Kurt-Wilhelm Stahl, Waisenmedizin e. V. Promoting Access to Care with Essential Medicine (PACEM), Non-Profit Non-Governmental Organization, Günterstalstraße 60, D-79100 Freiburg, Germany, E-mail: stahlkw@waisenmedizin.org.

These authors contributed equally to this work.

Disclosure: The patients’ parents have given their written consent to the LeiProtect treatment and to the anonymous publication of the treatment results.

Authors’ addresses: Dirk Debus, Department of Dermatology, Paracelsus Medizinische Privatuniversität, Klinikum Nürnberg, Prof.-Ernst-Nathan-Straße 1, Nürnberg, Germany, E-mail: dirk.debus@klinikum-nuernberg.de. Semra Genç and Philipp Kurz, Institute for Inorganic and Analytical Chemistry and Freiburg Material Research Center (FMF), Albert-Ludwigs-University Freiburg, Albertstraße 21, Freiburg, Germany, E-mails: semra.genc@ac.uni-freiburg.de and philipp.kurz@ac.uni-freiburg.de. Martin Holzer and Kurt Bauer, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Albert-Ludwigs-Universität, Hermann-Herder-Straße 9, Freiburg, Germany, E-mails: martin.holzer@pharmazie.uni-freiburg.de and bauer.kurt.freiburg@t-online.de. Ralph Heimke-Brinck and Martin Baier, Pharmacy Department, Universitätsklinikum Erlangen, Palmsanlage 3, Erlangen, Germany, E-mails: ralph.heimke-brinck@uk-erlangen.de and martin.baier@uk-erlangen.de. Heidi Sebald and Andrea Debus, Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstraße 3/5, Erlangen, Germany, E-mails: heidi.sebald@uk-erlangen.de and andrea.debus@uk-erlangen.de. Christian Bogdan, Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstraße 3/5, Erlangen, Germany, and Medical Immunology Campus Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossplatz 1, Erlangen, Germany, E-mail: christian.bogdan@uk-erlangen.de. Kurt-Wilhelm Stahl, Waisenmedizin e. V. Promoting Access to Care with Essential Medicine (PACEM), Non-Profit Non-Governmental Organization, Günterstalstraße 60, Freiburg, Germany, E-mail: stahlkw@waisenmedizin.org.

Save